Chloramphenicol encapsulated in poly-ε-caprolactone-pluronic composite: Nanoparticles for treatment of MRSA-infected burn wounds

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 2971-2984

  Kalita, Sanjeeb ^a   Devi, Banasmita ^a   Kandimalla, Raghuram ^a   Sharma, Kaustav Kalyan ^a   Sharma, Arup ^b   Kalita, Kasturi ^c   Kataki, Amal Chandra ^d   Kotoky, Jibon ^a  

^a INSTITUTE OF ADVANCED STUDY IN SCIENCE AND TECHNOLOGY   (India)

^b ASSAM AGRICULTURAL UNIVERSITY   (India)

^c Hyat Hospital   (India)

^d Dr B Borooah Cancer Institute ^*  (India)

Author keywords

Anti MRSA activity; Burn wound animal model; Chloramphenicol; Methicillin resistant Staphylococcus aureus; Nanoparticle; PCL pluronic

Indexed keywords

CHLORAMPHENICOL; NANOCOMPOSITE; POLOXAMER; POLYCAPROLACTONE; ANTIINFECTIVE AGENT; DRUG CARRIER; NANOPARTICLE; POLYESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BURN INFECTION; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG DELIVERY SYSTEM; DRUG EFFECT; ERYTHROCYTE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; MCF 7 CELL LINE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; SURVIVAL RATE; TIMED DRUG RELEASE; WOUND HEALING; ZETA POTENTIAL; ANIMAL; BURN; CELL SURVIVAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; FEMALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; TUMOR CELL LINE; WOUND INFECTION;

ANIMALIA; BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BURNS; CELL LINE, TUMOR; CELL SURVIVAL; CHLORAMPHENICOL; DISEASE MODELS, ANIMAL; DRUG CARRIERS; ERYTHROCYTES; FEMALE; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; NANOPARTICLES; POLOXAMER; POLYESTERS; WOUND INFECTION;

EID: 84928150437     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S75023     Document Type: Article

References (45)

1. Horvath EE, Murray CK, Vaughan GM, et al. Fungal wound infection (not colonization) is independently associated with mortality in burn patients. Ann Surg. 2007;245(6):978-985.
2. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin Microbiol Rev. 2006;19(2):403-434.
3. Alexis A, Carrer DP, Droggiti DI, et al. Immune responses in relation to the type and time of thermal injury: an experimental study. Injury. Epub 2014 Oct 31.
4. Chamania S, Hemvani N, Joshi S. Burn wound infection: Current problem and unmet needs. Indian J Burns. 2012;20(1):18-22.
5. Lederer JA, Rodrick ML, Mannick JA. The effects of injury on the adaptive immune response. Shock. 1999;11(3):153-159.
6. Fong J, Wood F. Nanocrystalline silver dressings in wound management: a review. Int J Nanomedicine. 2006;1(4):441-449.
7. Zorgani AA, Shahen A, Zaidi M, Franka M. A profile and spectrum of four cases of methicillin-resistant Staphylococcus aureus in a burns intensive care unit. Ann Burns Fire Disasters. 2006;19(1):5-10.
8. Katakura T, Yoshida T, Kobayashi M, Herndon DN, Suzuki F. Immunological control of methicillin-resistant Staphylococcus aureus (MRSA) infection in an immunodeficient murine model of thermal injuries. Clin Exp Immunol. 2005;142(3):419-425.
9. Jacobsen F, Fisahn C, Sorkin M, et al. Efficacy of topically delivered moxifloxacin against wound infection by Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55(5):2325-2334.
10. Fayyaz M, Mirza IA, Ahmed Z, Abbasi SA, Hussain A, Ali S. In vitro susceptibility of chloramphenicol against methicillin-resistant Staphylococcus aureus. J Coll Physicians Surg Pak. 2013;23(9):637-640.
11. Govender T, Riley T, Ehtezazi T, et al. Defining the drug incorporation properties of PLA-PEG nanoparticles. Int J Pharm. 2000;199(1):95-110.
12. Atyabi F, Moghaddam FA, Dinarvand R, Zohuriaan-Mehr MJ, Ponchel G. Thiolated chitosan coated poly hydroxyethyl methacrylate nanoparticles: synthesis and characterization. Carbohydr Polym. 2008;74(1):59-67.
13. Ting WW, Vest CD, Sontheimer RD. Review of traditional and novel modalities that enhance the permeability of local therapeutics across the stratum corneum. Int J Dermatol. 2004;43(7):538-547.
14. Bonina FP, Puglia C, Barbuzzi T, et al. In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur J Pharm Sci. 2001;14(2):123-134.
15. Bouchemal K, Briançon S, Perrier E, Fessi H, Bonnet I, Zydowicz N. Synthesis and characterization of polyurethane and poly(ether urethane) nanocapsules using a new technique of interfacial polycondensation combined to spontaneous emulsification. Int J Pharm. 2004;269(1):89-100.
16. Shim J, Seok Kang H, Park WS, Han SH, Kim J, Chang IS. Transdermal delivery of mixnoxidil with block copolymer nanoparticles. J Control Release. 2004;97(3):477-484.
17. Alvarez-Román R, Naik A, Kalia YN, Guy RH, Fessi H. Enhancement of topical delivery from biodegradable nanoparticles. Pharm Res. 2004;21(10):1818-1825.
18. Alvarez-Román R, Barré G, Guy RH, Fessi H. Biodegradable polymer nanocapsules containing a sunscreen agent: preparation and photoprotection. Eur J Pharm Biopharm. 2001;52(2):191-195.
19. Jiménez MM, Pelletier J, Bobin MF, Martini MC. Influence of encapsulation on the in vitro percutaneous absorption of octyl methoxycinnamate. Int J Pharm. 2004;272(1-2):45-55.
20. Ma Y, Zheng Y, Zeng X, et al. Novel docetaxel-loaded nanoparticles based on PCL-Tween 80 copolymer for cancer treatment. Int J Nanomedicine. 2011;6:2679-2688.
21. Kim DY, Rhee YH. Biodegradation of microbial and synthetic polyesters by fungi. Appl Microbiol Biotechnol. 2003;61(4):300-308.
22. Suksiriworapong J, Sripha K, Kreuter J, Junyaprasert VB. Functionalized (poly(ε-caprolactone))2-poly(ethylene glycol) nanoparticles with grafting nicotinic acid as drug carriers. Int J Pharm. 2012;423(2):562-570.
23. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1-18.
24. Das RK, Kasoju N, Bora U. Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells. Nanomedicine. 2010;6(1):153-160.
25. Li P, Dai NY, Zhang JP, Wang AQ, Wei Q. Chitosan-alginate nanoparticles as a novel drug delivery system for nifedipine. Int J Biomed Sci. 2008;4(3):221-228.
26. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2001;48(2-3):139-157.
27. Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985;60(4):110-111.
28. Kassem MA, ElMeshad AN, Fares AR. Lyophilized sustained release mucoadhesive chitosan sponges for buccal buspirone hydrochloride delivery: formulation and in vitro evaluation. AAPS Pharm Sci Tech. Epub 2014 Nov 6.
29. Mathew ST, Devi SG, KV S. Formulation and evaluation of ketorolac tromethamine-loaded albumin microspheres for potential intramuscular administration. AAPS Pharm Sci Tech. 2007;8(1):14.
30. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55-63.
31. Yang ZG, Sun HX, Fang WH. Haemolytic activities and adjuvant effect of Astragalus membranaceus saponins (AMS) on the immune responses to ovalbumin in mice. Vaccine. 2005;23(44):5196-5203.
32. Kalita S, Kumar G, Karthik L, Rao KVB. Phytochemical composition and in vitro hemolytic activity of Lantana camara L. (Verbenaceae) leaves. Pharmacologyonline Newsletter. 2011;1:59-67.
33. Serrano DR, Hernández L, Fleire L, et al. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations. Int J Pharm. 2013;447(1-2):38-46.
34. Murugan K, Senthilkumar B, Senbagam D, Al-Sohaibani S. Biosynthesis of silver nanoparticles using Acacia leucophloea extract and their antibacterial activity. Int J Nanomedicine. 2014;9:2431-2438.
35. Gajbhiye M, Kesharwani J, Ingle A, Gade A, Rai M. Fungus-mediated synthesis of silver nanoparticles and their activity against pathogenic fungi in combination with fluconazole. Nanomedicine. 2009;5(4):382-386.
36. Irobi ON, Daramola SO. Antifungal activities of crude extracts of Mitracarpus villosus (Rubiaceae). J Ethnopharmacol. 1993;40(2):137-140.
37. Rotimi VO, Laughon BE, Bartlet JG, Mosadomi HA. Activities of Nigerian chewing stick extracts against Bacteroides gingivalis and Bacteroides melaninogenicus. Antimicrob Agents Chemother. 1998;32(4):598-600.
38. Sande L, Sanchez M, Montes J, et al. Liposomal encapsulation of vancomycin improves killing of methicillin-resistant Staphylococcus aureus in a murine infection model. J Antimicrob Chemother. 2012;67(9):2191-2194.
39. Sanchez DA, Schairer D, Tuckman-Vernon C, et al. Amphotericin B releasing nanoparticle topical treatment of Candida spp. in the setting of a burn wound. Nanomedicine. 2014;10(1):269-277.
40. Scholes PD, Coombes AG, Illum L, et al. Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS. J Control Release. 1999;59(3):261-278.
41. Zhang Y, Tang L, Sun L, et al. A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment. Acta Biomater. 2010;6(6):2045-2052.
42. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505-515.
43. Florence AT. Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discov Today Technol. 2005;2(1):75-81.
44. Yan F, Zhang C, Zheng Y, et al. The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine. 2010;6(1):170-178.
45. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement (M100-S22). Wayne, PA: CLSI; 2012.